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Abstract
Background: Polycystic liver disease (PLD) is defined as having more than 20 liver cysts and can present as a severe
and disabling condition. Most symptoms are caused by the mass effect of the liver size and include abdominal pain
and distension. The somatostatin analogues octreotide and lanreotide have proven to reduce polycystic liver volume.
mTOR inhibitors such as everolimus inhibit cell proliferation and might thereby reduce growth of liver cysts. This trial
aims to assess the benefit of combination therapy of everolimus and octreotide compared to octreotide monotherapy.
In this study we present the structure of the trial and the characteristics of the included patients.
Methods/design: This is a randomized open-label clinical trial comparing the effect of 12 months of everolimus
and octreotide to octreotide monotherapy in PLD patients. Primary outcome is change in liver volume determined
by CT-volumetry. Secondary outcomes are changes in abdominal symptoms and quality of life. Moreover, safety
and tolerability of the drugs will be assessed.
Discussion: This trial will compare the relative efficacy of combination therapy with octreotide and everolimus to
octreotide monotherapy. Since they apply to different pathways of cystogenesis we expect that combining
octreotide and everolimus will result in a cumulative reduction of polycystic liver volume.
Trial registration number: ClinicalTrials.gov: NCT01157858
Background
Polycystic liver disease (PLD) is a condition that is arbi-
t r a r i l yd e f i n e da st h ep r e s e n c eo fa tl e a s t2 0l i v e rc y s t s .
The two genetic distinct disorders autosomal dominant
polycystic liver disease (PCLD) and autosomal dominant
polycystic kidney disease (ADPKD) are most frequently
responsible for PLD [1]. In ADPKD there are polycystic
kidneys which can be accompanied by liver cysts in up
to 87% of the patients, depending on age and severity of
renal impairment [2]. The phenotype of PLD can vary
widely but in most advanced cases impairs quality of life
by the mechanical complaints caused by the massively
enlarged liver [3].
Until recently, surgical procedures were the only treat-
ment options to reduce polycystic liver volume. How-
ever, these invasive procedures are accompanied by
relatively high morbidity and there is a small but detect-
able procedure related mortality [1]. In the last few
years, medical treatment options have been explored as
an alternative to invasive therapy. Somatostatin analo-
gues by virtue of reducing cAMP in the cholangiocytes
that line the cyst. The first signal of efficacy came from
experimental studies in rodent PLD models where
octreotide suppressed liver (-19%) and liver cyst (-40%)
volumes [4]. This concept was further reinforced by sev-
eral randomized clinical trials that demonstrated that a
6-12 month somatostatin analogue therapy with octreo-
tide or lanreotide reduces liver volume by 15-38% [5-9].
Recently, mTOR inhibitors have proven to have an
effect on polycystic liver volume as well [10].
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and inhibit mTOR, and thereby exert antiproliferative,
antiangiogenetic and tumor-progression blocking cap-
abilities that might serve preventing uncontrolled cho-
langiocyte cell proliferation. Treatment with mTOR
inhibitors dramatically reduced cyst volume in experi-
mental models [11-15]. An observational trial in
ADPKD patients who received a kidney transplant
observed that sirolimus reduced polycystic liver volumes
by 12% compared to an increase of 14% in patients who
received standard treatment with tacrolimus [10].
We were interested whether mTOR inhibitors would
be able to augment the PLD reducing effect of somatos-
tatin analogues. Therefore we set out to design a clinical
trial that investigates the effect of combining a somatos-
tatin analogue (octreotide) and a mTOR inhibitor (ever-
olimus) in a randomized fashion to assess whether
combination therapy has additional effect over somatos-
tatin analogue monotherapy in PLD volume reduction.
Patients and Methods
Study population
All symptomatic PLD patients (≥ 20 liver cysts on CT
scanning) with PCLD or ADPKD, that meet the follow-
ing eligible criteria are suitable for participation in this
study.
Inclusion criteria
￿ 18 < age ≤ 70 years
￿ Polycystic liver disease (PCLD or ADPKD), defined
as ≥ 20 liver cysts
￿ Total liver volume must be at least 2500 mL
￿ Symptomatic defined as ECOG-PS ≥ 1( E C O G -
Performance Scale: indicates how disease affects the
daily living abilities of the patient; scale ranges from
0 to 5 in order of severity), and having at least three
out of ten PLD symptoms:
- Abdominal pain
- Abdominal distension
- Abdominal fullness
- Dyspnea
- Early satiety
- Back pain
- Nausea/vomiting
- Anorexia
- Weight loss
- Jaundice
￿ Informed consent, patients are willing and able to
comply with the study drug regimen and all other
study requirements
Exclusion criteria
￿ Use of oral contraconceptives or estrogen
supplementation
￿ Females who are pregnant or breast-feeding or
patients of reproductive potential not employing an
effective method of birth control; women of child-
bearing potential must have a negative serum preg-
nancy test within 48 hours prior to the
administration of study medication
￿ Intervention (aspiration or surgical intervention)
within three months before baseline
￿ Treatment with somatostatin analogues within
three months before baseline
￿ Patients with a kidney transplant
￿ History or other evidence of chronic pulmonary
disease associated with functional limitation
￿ History of severe cardiac disease (e.g. NYHA Func-
tional Class III or IV, myocardial infarction within 6
months, ventricular tachyarrhythmias requiring
ongoing treatment, unstable angina or other significant
cardiovascular diseases); in addition, patients with
documented or presumed coronary artery disease or
cerebrovascular disease should not be enrolled
￿ History or other evidence of severe illness or any
other conditions which would make the patient, in
the opinion of the investigator, unsuitable for the
study
￿ Symptomatic gallstones (octreotide decreases gall
bladder volume)
￿ Hypercholesterolemia (fasting cholesterol > 8
mmol/l) or hypertriglyceridaemia (> 5 mmol/l) not
controlled by lipid lowering therapy
￿ Granulocytopenia (white blood cell < 3,000/mm3)
or thrombocytopenia (platelets < 100,000/mm3)
￿ Infection with hepatitis B, hepatitis C, HIV, TBC
(in medical history)
￿ Mental illness that interferes with the patient abil-
ity to comply with the protocol
￿ Drug or alcohol abuse within one year of baseline
￿ Co-medication with strong inhibitor of CYP3A4
and/or P glycoprotein like voriconazole, ketocona-
zole, diltiazem, verapamil, erythromycin or with a
strong CYP3A4 and or P-glycoprotein inductor like
rifampicin
￿ Known hypersensitivity to everolimus or one of its
excipients
￿ Enrolment in another clinical trial of an investiga-
tional agent while participating in this study
￿ Moderate or severe reaction on contrast in medical
history
￿ Treatment with I131 during the course of the trial
￿ Use of metformine
￿ Morbus Kahler or Morbus Waldenstrom with
excretion of light chains in urine in medical history
￿ Kidney dysfunction (MDRD-GFR < 60 ml/min/
1.73m2 and endogenous creatinine clearance < 60
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in case of decreased body muscle mass, exact endo-
genous creatinine clearance is measured using serum
and urine creatinine
Study design and setting
The ELATE trial is a single-centre, randomized, open-
label parallel study in adult symptomatic PLD due to
PCLD and ADPKD. The trial is performed in the Rad-
boud University Nijmegen Medical Centre, Nijmegen,
The Netherlands. Duration of treatment is 48 weeks.
The design of the trial is showed in Figure 1.
Randomization, blinding and treatment allocation
Patients are randomized to one of the treatment arms
in a 1:1 ratio (Figure 1). An eligible patient is assigned
t oat r i a l - c o d e( r a n d o m i z ation number). A computer
generated randomization list is made by an indepen-
dent biostatistics unit using a permuted block design
with a random block size of 4 to guarantee a balanced
allocation. PLD liver volume will be assessed using
unmarked CT scans to assure that the assessor is
blinded to the assigned treatment. All CT scans will be
anonymized and all dates will be removed, so the clini-
cal investigator is unfamiliar which CT scan belongs to
which patient and whether the CT scan is dated prior
to treatment or after treatment. All CT scans will be
assessed by the same operator (MC). The CT scans
will be reassessed blindly by an independent
investigator.
Treatment arms
The ELATE trial has two treatment arms. One arm
receives a combination of octreotide and everolimus,
while the other arm will receive octreotide monotherapy
without placebo. Patients in both arms are treated with
octreotide LAR (Sandostatine LAR, Novartis) 40 mg
intramuscularly every 28 days. Since Sandostatine LAR
is not provided in dosages of 40 mg, all patients receive
two subsequent injections of 20 mg. Everolimus is
started in an initial dose of 2,5 mg daily and is moni-
tored by measuring trough levels. We maintain trough
levels within 3-8 ng/mL. Trough levels are assessed two
weeks after starting everolimus and a check is per-
formed after 24 weeks, at control visit 4. When trough
levels exceed these values, the frequency of dosing is
adjusted. Patients were requested to take their medica-
tion at fixed times to avoid fluctuations in the trough
levels. Furthermore, patients are advised to avoid sun
exposure, and avoid drugs or food that are known to
interact with everolimus.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Octreotide 40 mg / 4 weeks 
Octreotide 40 mg / 4 weeks 
Everolimus 2.5 mg / day 
Screening and 
randomization 
CT  CT 
-4  0  48  2  6  12  24  36 
Baseline  End trial
Figure 1 Trial design of the ELATE trial. All patients are screened for eligibility and the patients who suit the criteria are randomized in an
equal ratio to either the octreotide monotherapy arm or the octreotide and everolimus arm. All patients receive a CT scan at baseline and after
12 months of treatment. Control visits are performed at 2, 6, 12, 24, 36 and 48 after baseline.
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The main hypothesis of the study is that the combina-
tion of everolimus and octreotide gives more reduction
of PLD volume when compared to octreotide
monotherapy.
Primary outcome
Primary outcome is the change of total liver volume
between the two treatment arms in terms of percentage
from baseline to 12 months as determined by CT-
volumetry.
Secondary outcomes
Secondary outcomes of the ELATE trial are change of
kidney volume from baseline to 12 months in ADPKD
patients as determined by CT-volumetry, change in
symptoms, as assessed by GI questionnaire [16], and
change in quality of life, as assessed by Euro-QoL ques-
tionnaire [17]. Other secondary outcomes are the pro-
portion of patients having any reduction in total liver
volume after 12 months and all adverse events in these
12 months. Furthermore, vital signs, laboratory and
safety parameters are monitored at all visits during 12
months of treatment.
Data collection
Patients are seen at baseline, and after 2, 6, 12, 24, 36
and 48 weeks of treatment. During these visits medical
history is taken and vital signs and laboratory tests are
assessed. During medical history taking patients are
asked for concomitant medication and adverse events. A
CT scan is made at baseline and after 48 weeks of treat-
ment. In addition we administer GI and EuroQoL ques-
t i o n n a i r e sa tt h e s et i m ep o i n t s .A l ld a t aa r ec o m p l e t e d
on a Case Report Form (CRF) and collected in a data-
base. The parameters that are asked for at the different
visits are found below.
Baseline
￿ Written informed consent
￿ Eligibility criteria check
￿ Assessment of ECOG-PS score (see Inclusion
criteria)
￿ Verification of the diagnosis of polycystic liver
disease
￿ General characteristics: initials, date of birth (dd/
mm/yyyy), age (years), gender, weight (kg), height
(cm), blood pressure (mmHg), heart rate and ethnic
background
￿ Pregnancy test in females between 18-50 years (<7
days before baseline)
￿ Hepatitis B, C, HIV, TBC screening: HBsAg, anti-
HCV and HIV in blood and Mantoux and chest X-
ray
￿ Serum storage for future reference (6 ml)
￿ GI symptom questionnaire
￿ EuroQoL questionnaire
￿ CT scan of the liver
Every visit
￿ Concomitant medication
￿ Adverse events
￿ Drug accountability
￿ Physical examination, blood pressure and heart
rate
￿ Weight
￿ Lab hematology
￿ Lab chemistry
End of treatment
￿ GI symptom questionnaire
￿ EuroQoL questionnaire
￿ CT scan with contrast of the liver
Withdrawal of individual subjects
Patients must be withdrawn from the study for any of
the following reasons:
￿Withdrawal of informed consent
￿Pregnancy
￿Consistently fails to adhere to study drug regimen
or protocol requirements
￿Study drug discontinuation
￿Unacceptable toxicity (grade 4 adverse events)
￿Surgical intervention during trial
￿Patients also should be withdrawn at any time if the
investigator concludes that it would be in the
patient’s best interest for any reason.
If premature withdrawal occurs for any reason, the
investigator must determine the primary reason for a
patient’s premature withdrawal from the study and
record this information on the Study Completion CRF
(case report form). We will not allow replacement of
study participants into the study.
Study procedures
All patients will be subjected to an abdominal CT with
lower radiation dose than usual, and with intravenous
contrast, following a standard protocol designed for this
trial. CT scans will be anonymized as to allow a blinded
assessment of the liver volume. The liver volume will be
measured using sequential measurement of the liver
outline of subsequent slices [7]. The slices will be out-
lined manually every 9-10 mm from the cranial to cau-
dal until the total liver has been captured. We use
Pinnacle3
® v8.0d (Philips Electronics NV, Eindhoven,
the Netherlands). This software interpolates the
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indicated circumference. The intraobserver variability
has been assessed by correlating 2 measurements of 5
different CT scans by the first author (MC). Subse-
quently, interobserver variability was assessed by corre-
lating 2 measurements that were done by 2 independent
researchers of 5 different CT scans. The results of these
assessments are shown in Figure 2.
Sample size calculation
Somatostatin analogues reduce liver volume by 57 mL
after 12 months of treatment [7], while mTOR inhibi-
tors give a reduction of liver volume of 223 mL [10].
We assumed that the common standard deviation is 130
mL using a two group t-test with a 0.01 two-sided sig-
nificance level. To detect a difference in means of 166
mL with 90% power, a sample size of 20 in each group
is needed. Taken into account a dropout rate of 10%,
the minimal sample size needs to be 22 patients per
group, so the group totals 45 patients.
Statistical analysis
Analyses will be performed using SPSS software. Inten-
tion-To-Treat analyses will be used for all clinical out-
come variables. The Intention-To-Treat population
includes all patients who received at least one dose of
study medication. When patients have prematurely ter-
minated the trial, they are asked to undergo a CT scan
after stop of treatment. These values will be used
instead of end-of-treatment values for ITT-analysis.
When no CT scan is available after premature termina-
tion of the trial or the patients drops out in the first
month of the trial, the value at start of treatment will be
used for ITT-analysis. We use “last value carried for-
ward” for missing observations other than CT scan. We
will provides a sensitivity analysis for missing data
assumptions. Parallel analyses conducted on the Per-
Protocol population will be performed. The Per-Protocol
population is defined as all patients who have received
all 12 injections of octreotide within a week around the
set date, and in the combination therapy group, all
patients who have received at least 80% of the total
amount of dosages of everolimus at one year from
baseline.
Disease progression will be determined primarily by
dividing the change between the baseline and final scans
by the duration of follow-up. The volume of the liver
will be determined as indicated before.
Treatment comparisons for the continuous outcome
variables will be based on an analysis of covariance
(ANCOVA model), with baseline and treatment
included as covariates and the absolute change from
baseline as the dependent variable.
For the primary endpoint, the effect of treatment will
be analyzed using the Mann Whitney U test. All labora-
tory results out of the normal range will be listed. All
statistical analyses will be two-sided with a critical sig-
nificance level of 5%. Frequency tables will be compiled
for Adverse Events classified according to the standard
WHO-ART Body System Dictionary and preferred
terms.
Ethics
The protocol and the patient information forms were
approved by the Medical Ethics Committee. This study
is performed in accordance with the protocol, the guide-
lines of Good Clinical Practice/ICH, the principles of the
Declaration of Helsinki 1964 as modified by the 52nd
WMA General Assembly, Edinburgh, Scotland, October
2000 including two notes of clarification paragraph 29
and 30, and the local national laws governing the con-
duct of clinical research studies.
Discussion
The study has been submitted to clinicaltrials.gov and
the trial identifier is NCT01157858. The ELATE trial is
Figure 2 Intraobserver and interobserver variability. The figure on the left panel shows the intraobserver variability, which is the accuracy of
a single researcher that has measured the same CT scan at two different times. The correlation between the consequent measurements is 1.00
(p < 0.01). The figure on the right panel shows the interobserver variability, which is the accuracy between two researchers who measured the
same CT scan. The correlation between the measurements is 1.00 (p < 0.01).
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everolimus and octreotide is more effective in reducing
polycystic liver volume in PLD patients than octreotide
monotherapy. Furthermore, we will assess changes in
abdominal symptoms and quality of life.
All patients were included between June 2010 and July
2011 and the last patient will complete the trial in July
2012. Initially, we intended to include only PCLD
patients, because we wanted to keep the group as
unmixed as possible. However, after a rapid inclusion in
the first months, inclusion slowed because of an insuffi-
cient number of patients who met the inclusion criteria
( F i g u r e3 ) .T h ep r e v a l e n c eo fP C L Di so n l y1 : 1 5 8 . 0 0 0
[3], while that of ADPKD, another disorder with PLD as
a presenting feature, has been estimated at 1:1000 [18].
After reconsideration and in an effort to provide ade-
quate power to the study the inclusion criteria were
expanded and ADPKD patients were also allowed to
participate. Finally, 45 patients were randomized to
either of the treatment arms. Baseline characteristics of
all trial participants are stated in Table 1. The groups
were equal, as there were no differences found between
the treatment arms.
There is a fair amount of data from a number of clini-
cal trials that demonstrated the efficacy of somatostatin
analogues on PLD volume [5-9,19]. The effect size how-
ever differs widely. On the basis of clinical case observa-
tions we reported that somatostatin analogues reduced
PLD volume by 14-38% [5]. In a subsequent case series
of 8 patients we found a reduction of 3.0% [6]. A formal
6-month RCT in 54 patients demonstrated that
lanreotide reduced PLD volume by 2.9% when compared
to baseline values [7]. Two other RCTs showed that
octreotide LAR 40 mg reduced liver volumes by 4.9%
when given for 12 months [8], while 6 months octreo-
tide 40 mg decreased total liver volume by 4.4% [9].
Therefore it is reasonable to assume that we will see a
decrease of PLD volume during the course of our trial.
The key question is whether an add-on treatment with
everolimus will be able to further decrease PLD volume
to values seen in the observational study by Qian [10].
Just prior to start of recruitment of this trial the results
from 2 landmark papers studying the effect of mTOR
inhibitors in ADPKD were published [20,21]. The
SUISSE ADPKD group performed a 18-month rando-
mized open-label clinical trial with sirolimus 2 mg com-
pared to standard treatment. After 18 months of
treatment, there was no difference in kidney cyst growth
between the groups [20]. Another group studied everoli-
mus in 433 ADPKD patients in a 2-year, double-blind
trial. In contrast to the SUISSE trial, everolimus attenu-
ated the increase of total kidney volume, but did not
slow the progression of renal impairment [21]. PLD
liver volume was not assessed in these trials. The most
important difference with our study is that we use PLD
volume reduction as the primary outcome, while these 2
Figure 3 Course of inclusion. This figure shows at which
frequency the patients entered the trial. In the first 5 months of
inclusion was very rapid, but then went flat for a few months. At
month 11 the protocol was changed to such an extent that ADPKD
patients were also allowed to participate in the trial. This reignited
inclusion and the intended sample size was reached within 3
months.
Table 1 Baseline characteristics of patients in the ELATE
trial
Octreotide/everolimus
(n = 22)
Octreotide
(n = 23)
Age (yr) 52.9 (8.7) 50.7 (8.0)
Gender (m/f) 3/19 2/21
Diagnosis (PCLD/ADPKD) 9/13 6/17
Mutation in PCLD patients
PRKCSH 10 5
SEC63 14
Body mass index (kg/m
2) 28.0 (3.5) 28.3 (3.9)
Systolic blood pressure
(mmHg)
134 (14) 135 (15)
Diastolic blood pressure
(mmHg)
87 (11) 84 (9)
Haemoglobin (mmol/L) 8.2 (0.7) 8.2 (0.7)
White blood count (*10
9/L) 6.5 (1.6) 6.2 (1.4)
Thrombocyte count (*10
9/L) 212 (56) 210 (62)
Creatinine (μmol/L) 72 (16) 68 (11)
Albumin (g/L) 40 (3) 40 (2)
Bilirubin (μmol/L) 14 (7) 14 (5)
g-Glutamyl Transferase (U/L) 162 (131) 154 (122)
Glucose (mmol/L) 5.0 (0.5) 5.0 (0.8)
Cholesterol (mmol/L) 4.9 (0.9) 4.7 (1.0)
CA19-9 (E/mL) 123 (168) 134 (172)
All continuous variables are stated as mean (SD)
All PCLD patients underwent mutation analysis, no mutation analysis was
performed on ADPKD patients
There were no differences between the treatment arms
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measure.
PLD liver volume was assessed through a retrospective
analysis of a trial that compared a sirolimus-containing
immunosuppression regimen with a tacrolimus-contain-
ing regimen in 16 renal transplant recipients with
ADPKD. Sirolimus given for an average of 19 months
decreased PLD volume by 11.9%, whereas tacrolimus for
a comparable duration increased PLD volume by 14.1%
[10]. These data led to the assumption that a large effect
size of everolimus treatment is realistic.
We have intentionally chosen to combine octreotide
and everolimus instead of introducing an everolimus
monotherapy arm, because we expect to find a larger
reduction of liver volume with combination therapy
than with monotherapy. We hope to detect an addi-
tional effect, because combination treatment targets two
divergent pathways of cystogenesis. Above all, the struc-
ture of our trial addresses the issue whether add-on
therapy augments the established effect of octreotide.
As with the 2 other trials employing mTOR inhibitors
in ADPKD [20,21] we elected not to use a placebo in
the control arm. The therapeutic drug monitoring of
everolimus effectively unblinds the trial. In addition, we
expect that patients will have significantly more side-
effects resulting from everolimus treatment than from
octreotide. Patient will recognise this and therefore
blinding will be ineffective. However, we will measure
PLD volume blind to date or patient, since all CT scans
will be randomized and disposed of any study dates.
This assures that the assessor is unaware whether the
CT scan was made at baseline or on follow-up.
Everolimus is initially dosed at 2.5 mg daily and
trough levels are maintained between 3-8 ng/mL to
have as minimal adverse events as possible. We have
adapted our everolimus treatment regimen following
those used in solid organ transplantation. Here, dosages
are relatively well tolerated. In addition, the treatment
schedule used in our RCT is equivalent to the dosages
used in the previous trials using mTOR inhibitors in
ADPKD patients [20,21].
We believe that there is still an ongoing quest for
drugs that can further decrease PLD liver volume and
thereby improve quality of life. Consequently, we want
to assess whether the combination of somatostatin ana-
logues and mTOR inhibitors works cumulative on
reduction of liver volume. Furthermore, by exploring all
possible medical treatment options, we eventually hope
to contribute a treatment protocol to the field that most
effectively reduces symptoms and signs of PLD.
Trial status
Ongoing
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